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ABSTRACT
Aims: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is standard care for neo-
vascular age-related macular degeneration (nAMD), but the recommended monthly injection regimen
is burdensome. Evidence suggests low injection/monitoring frequencies in clinical practice and sub-
optimal vision outcomes. This observational cohort study uses administrative claims data from the
French national healthcare system to assess anti-VEGF treatment patterns and nAMD-specific health-
care resource demands and costs.
Patients and methods: nAMD patients 50 years initiating intravitreal ranibizumab, aflibercept or
bevacizumab treatment (2014–2015), and propensity score-matched non-nAMD patients (controls),
were identified from the Echantillon Generaliste de Beneficiaires database. Outcomes of interest
included anti-VEGF treatment patterns, and healthcare resource utilization and associated costs of
patients vis-a-vis controls over 24 months.
Results: Study patients (n¼ 355) received (mean) 5.2 and 2.4 anti-VEGF injections over 0–12 and
12–24 months, respectively. Most patients (79.0%) remained on their initial anti-VEGF agent; among
treatment switchers, the most common transition was from ranibizumab to aflibercept. During follow-
up, nAMD patients were more likely than controls to require ophthalmology visits (99.7% vs. 44.8%),
ocular procedures (optical coherence tomography/angiography/fundoscopy) (96.9% vs. 27.2%), cataract
surgery (13.0% vs. 6.7%), and medical transports (38.0% vs. 31.9%). Mean numbers of ophthalmology
visits (25.1 vs. 1.2) and medical transports (6.0 vs. 3.5) were higher (p<.01) among nAMD patients.
Total reimbursed costs were two-fold higher for nAMD patients than controls (mean e16,799 vs.
e8,255) due to higher treatment costs (e6,847 vs. e1,156), medical fees (e1,858 vs. e295), hospital fees
(e6,396 vs. e5,235), and transport costs (e358 vs. e259). Excess total healthcare cost was (mean) e5,279
and e7,918 over the first 12 and 24 months of treatment, respectively.
Conclusions: Current intravitreal anti-VEGF treatment and monitoring requirements place a consider-
able economic burden on the French healthcare system. New intravitreal therapies with extended dos-
ing intervals and predictable efficacy might reduce demand for ophthalmology services.
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Introduction
Age-related macular degeneration (AMD) is the leading cause
of irreversible vision impairment and blindness among the
elderly throughout the developed world1 and has a pro-
foundly detrimental effect on the independence and quality
of life of affected individuals2–4. Neovascular or “wet” AMD
(nAMD), characterized by macular neovascularization, intra-
or subretinal exudation and hemorrhage, is the most aggres-
sive form of the disease and accounts for the great majority
(90%) of cases of AMD-related severe vision loss and blind-
ness5. Advanced age is the major non-genetic risk factor for
the development of AMD6, and the prevalence and
associated socioeconomic burden of the disease can be
expected to increase as life expectancy improves. A recent
meta-analysis of cohort studies from the European Eye
Epidemiology consortium estimated that 13.2% of the
European population aged 70 years had early AMD and
3.0% had late AMD during the period 1990–20137. With
regard to nAMD, the European Eye Study (EUREYE) reported
an overall prevalence of 2.3% in Europeans aged 65 years8.
Based on current French demographic data (13.6 million
adults aged 65 years in January 2020)9, this prevalence rate
translates to approximately 312,000 adults in the 65-year
age-group with nAMD in France. Projections from the
Rotterdam Eye study data10 suggest that in France,
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approximately 36,000 individuals develop advanced AMD
each year, of whom 21,000 have nAMD11.
The advent of intravitreal anti-vascular endothelial growth
factor (anti-VEGF) therapy has revolutionized the manage-
ment of nAMD over the past 15 years, not only stabilizing
but in many cases reversing the vision damage caused by
nAMD12,13, and it is currently considered standard of care.
Important considerations in ensuring optimal long-term
vision outcomes with anti-VEGF therapy include the need for
early initiation of treatment after nAMD diagnosis, appropri-
ate intravitreal injection frequencies, and avoidance of treat-
ment delays14,15, which necessarily makes for protracted,
intensive and costly treatment regimens. Currently, three
anti-VEGF agents are prescribed for ophthalmological use in
France: ranibizumab (introduced in 2007), aflibercept (intro-
duced in 2013), and bevacizumab (granted a temporary use
recommendation for the nAMD indication in 2015). Recent
meta-analyses of direct comparative clinical trials of anti-
VEGF agents in nAMD would suggest that ranibizumab, bev-
acizumab and aflibercept offer comparable efficacy in terms
of their impact on visual acuity16, and similar ocular tolerabil-
ity profiles16,17. The frequent (typically monthly or bimonthly)
intravitreal dosing regimens recommended for these agents
are, however, difficult to sustain over the long term18, and
this has prompted the adoption of individualized, less bur-
densome pro re nata (PRN) and treat-and-extend dosing regi-
mens in clinical practice19,20.
Emerging therapies for nAMD, including sustained-release
anti-VEGF formulations, long-acting anti-VEGF agents, agents
that block non-VEGF pathways, sustained-delivery devices,
and genetic therapies, offer the prospect of reduced treat-
ment burden and improved vision outcomes21. Assessment
of the likely impact that these therapies will have on real-
world management of nAMD requires an understanding of
current anti-VEGF treatment patterns and costs, which vary
appreciably from country to country15. Information on the
medical management, healthcare resource utilization, and
associated costs of nAMD care in France is limited and often
outdated, predating the era of anti-VEGF therapy22–26. This
retrospective analysis of claims data was undertaken to pro-
vide an up-to-date picture of the epidemiology and treat-
ment of nAMD, as well as an assessment of nAMD-specific
healthcare resource demands and costs, in France.
Methods
This representative observational cohort study was based on
de-identified administrative claims data sourced from the
French national healthcare data system. The study was
designed in collaboration with an Independent Scientific
Committee and was exempt from legislation governing
research in human subjects.
Data source
The French healthcare system is based on universal health-
care insurance coverage. As part of this structure, the
national healthcare data system, SNIIRAM (Systeme National
d’Informations Inter-Regimes de l’Assurance Maladie), now
designated as the SNDS (Systeme National des Donnees de
Sante), prospectively collects and links anonymized patient-
level data from multiple sources, including reimbursed health
expenses in primary care and claims paid by the national
health insurance system to public and private hospitals.
SNIIRAM/SNDS captures medical and administrative data
from virtually all healthcare insurance plans, and currently
covers 98.8% of the French population, making it one of the
world’s largest and most representative databases of its
type27,28. SNIIRAM/SNDS provides information on all aspects
of healthcare utilization and associated costs, including
demographics, outpatient medical and paramedical care,
hospital admissions, diagnoses, procedures, laboratory tests,
chronic conditions, pharmacy prescriptions, medical trans-
ports, disability allowances, and sick leaves28. Cost informa-
tion includes total costs and reimbursement costs, allowing
healthcare expenses to be expressed from societal and
national health insurance perspectives28.
The EGB (Echantillon generaliste de beneficiaires) claims
database comprises a 1/97th randomly selected, representa-
tive sample of the SNIIRAM/SNDS database population
(approximately 780,000 individuals)28. Patient data are stored
and remain accessible for 20 years, making EGB the database
of choice for longitudinal analysis of the more common
chronic diseases27.
Study population
The EGB database was screened to identify patients who
received intravitreal anti-VEGF treatment between 1 January
2014 and 31 December 2017 (selection period). To avoid any
immediate disruption to treatment patterns arising from the
introduction of a new anti-VEGF agent, 2014 was chosen as
the start of the selection period as this was the first year in
which all three of the currently approved anti-VEGF treat-
ments (bevacizumab, ranibizumab, and aflibercept) were
available in France for the treatment of nAMD. Patient selec-
tion was terminated in 2017 since, at the time of the study
(2019), this was the latest year for which information was
available in the SNDS data system.
For study inclusion, patients were required (i) to be 50
years of age; (ii) to be continuously enrolled between 1
January 2009 and 31 December 2017 in a health insurance
scheme integrated into the EGB database; and (iii) to have at
least 2 reimbursement claims on separate dates between 1
January 2014 and 31 December 2017 for dispensation of
ranibizumab [Anatomic Therapeutic Chemical (ATC) code
S01LA04], aflibercept (ATC code S01LA05), or bevacizumab
(temporary use recommendation) (ATC code L01XC07) asso-
ciated with a diagnosis of degeneration of the macula and
posterior pole [International Classification of Diseases, Tenth
Revision (ICD-10) code H35.3) or a claim for intravitreal injec-
tion [Classification Commune des Actes Medicaux (CCAM) pro-
cedure code BGLB001] (Figure 1, Step 1). The date of the
first recorded reimbursement claim for anti-VEGF treatment
or intravitreal injection during the selection period was des-
ignated the index date. To ensure that anti-VEGF treatment
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was administered specifically for nAMD, the study excluded
patients with an in-hospital or long-duration disease (LDD)
diagnosis (2009–2017) of diabetes mellitus with ophthalmic
complications (i.e. diabetic cataract and diabetic retinopathy)
(ICD-10 codes E10.3–E14.3), macular edema secondary to ret-
inal vascular occlusion (ICD-10 codes H34.0, H34.1, H34.2,
H34.8, H34.9), or choroidal neovascularization secondary to
pathologic myopia (ICD-10 code H31.8), as well as patients
with 1 claims (2009–2017) for intravitreal dexamethasone
implant, or laser treatment specifically for diabetic retinop-
athy (Figure 1, Step 2). As a further safeguard, diabetic
patients without an associated in-hospital or LDD diagnosis
(2009–2017) of degeneration of the macula and posterior
pole (ICD-10 code H35.3) were excluded (Figure 1, Step 3).
Within the resulting population of anti-VEGF–treated
nAMD patients, the subgroup of patients with newly diag-
nosed nAMD—defined as having no recorded reimburse-
ment claim for nAMD in the 5 years before the index date—
was identified (incident cases). For a description of treatment
patterns and determination of healthcare resource utilization
and associated costs, the index date for selection of the
study population of incident nAMD patients was narrowed
to the period between 1 January 2014 and 31 December
2015 to allow 2 years of follow-up after treatment initiation
(Figure 1, Step 4).
A group of control subjects, comprising individuals aged
50 years who had no recorded diagnosis of nAMD and no
reimbursement claim for anti-VEGF treatment or intravitreal
injection between 2010 and 2017, was selected from the
general population available in the EGB database in
2014–2015. To quantify the burden of nAMD, control sub-
jects were matched and compared to study patients with
incident nAMD (3:1 ratio of controls to patients) using indi-
vidual propensity scores based on demographic and clinical
variables (age, gender, region of residence, cardiovascular
and respiratory disease history, and prior cataract surgery).
Outcomes
Baseline demographic and clinical characteristics of inci-
dent nAMD and control populations
Baseline sociodemographic characteristics (age, gender, geo-
graphic region of residence) and clinical characteristics,
including Charlson Comorbidity Index (CCI)29 at index date,
medical history (cardiovascular disease, respiratory disease,
diabetes, anxiety/depression, falls/fractures, glaucoma, cata-
ract, diabetic retinopathy, and endophthalmitis) and ocular
surgery history (glaucoma, cataract, retinal detachment, and
endophthalmitis surgery) over the 5-year pre-index period,
were described for patients with incident (2014–2015) nAMD
and for propensity score-matched controls. CCI was based on
19 comorbidities weighted for severity and was adjusted for
age30. Comorbidities of interest were identified from hospital
discharge and LDD diagnosis (ICD-10) codes, medical proced-
ure (CCAM) codes, and drug [ATC, Unites communes de dis-
pensation (UCD), and Code identifiant de Presentation (CIP)]
codes.
Anti-VEGF treatment patterns in the incident nAMD
population
Anti-VEGF treatment patterns, including the type of anti-
VEGF agent, number of intravitreal anti-VEGF injections
administered and anti-VEGF treatment switches, were
assessed at the patient level over the first 24 months post-
index in the incident nAMD population. Anti-VEGF treatment
switch was defined as a change from the use of treatment A
to treatment B within 6 months after the previous intravitreal
EGB population from January 2009 
to December 2017 (n = 528,625)
Patients with at least 2 reimbursments of 
anti-VEGF or intravitreal injections between 
January 1, 2014 and December 31, 2017 
(n = 2300)
Anti-VEGF–treated patients (n = 2239)
nAMD–treated patients (n = 1313)
Confirmed nAMD–treated patients (n = 1126)
Exclusion of patients with no anti-VEGF injection (n= 525,749)
Exclusion of patients with 1 anti-VEGF injection (n = 576)





Exclusion of patients with a confounding ocular disease (n = 926)
Exclusion of diabetic patients with no nAMD diagnosis (n = 187)
Exclusion of patients: 
•  Selected before January 1, 2014 and after December 31, 2015 
(n = 412)
•  With at least 1 reimbursement of anti-VEGF or intravitreal injection 
in the 5 years prior to index date (n = 377)
Study population (n = 355)
Figure 1. Patient selection algorithm.
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injection, with no subsequent administrations of treatment
A. Treatment switch-back was defined as the occurrence of a
solitary injection of treatment B interspersed between
sequential administrations of treatment A.
Healthcare resource utilization and costs in the incident
nAMD and control populations
Hospitalizations of interest (myocardial infarction, thrombo-
embolism, fall/fracture, and nAMD-related), emergency
department, outpatient ophthalmology and general practice
(all-cause) visits, ophthalmic procedures/examinations [optical
coherence tomography (OCT), fluorescein/indocyanine green
angiography, and fundoscopy], ocular surgery (glaucoma,
cataract, retinal detachment, and endophthalmitis proce-
dures), ophthalmic medication (intravitreal bevacizumab,
ranibizumab and aflibercept, and topical antibiotic/antisep-
tic/corticosteroid eyedrops), sick leaves, and medical trans-
ports over the first 24 months post-index were compared
between the incident nAMD population and control subjects.
Event rates (mean number of events per patient) were calcu-
lated for the entire study population, regardless of follow-up
duration (24 months) and, where available, for those
patients who completed 24 months of follow-up. Direct med-
ical costs, including medical, surgical and paramedical (nurse,
physiotherapist and orthoptist) fees, hospitalization, out-
patient ophthalmology, pharmacy, medical transports, and
sick leave costs reimbursed over this period were extracted
from the EGB database and presented from the perspective
of the French Health Insurance system. Cost comparisons
between patient and control groups were conducted from 6
months pre-index onward to capture the additional cost of
nAMD diagnosis. Costs were reported in Euros at 2018 val-
ues; costs that occurred prior to 2018 were adjusted to 2018
values31. Cost analyses were conducted in accordance with
French National Authority for Health (Haute Autorite de
Sante) guidelines on pharmacoeconomic evaluation32.
Epidemiology of nAMD
The numbers of incident cases of anti-VEGF–treated nAMD
identified in the EGB database population in 2014–2017
were extrapolated to provide an estimate of the number of
people with incident anti-VEGF–treated nAMD in France dur-
ing the same period. For this epidemiological analysis, the
definition of “incident anti-VEGF–treated nAMD” was relaxed
from that applied to the study population to allow inclusion
of diabetic (non-DME) patients without an accompanying in-
hospital or LDD diagnosis of nAMD (i.e. the Step 3 exclusion
criterion was lifted; Figure 1). Adoption of this revised defin-
ition stemmed from concern that the requirement for an in-
hospital or LDD diagnosis of nAMD was too restrictive,
potentially resulting in underestimation of the actual number
of nAMD-treated patients in the database population.
Numerical projections were based on the ratio of the EGB
database population on 1 January 2017 to the estimated
French national population in 2017, and were adjusted to
account for differences in the age and gender profiles of the
two populations.
Statistical analyses
Continuous data were summarized as mean± standard devi-
ation values, and categorical data were presented as fre-
quencies. Propensity scores of study patients and controls
subjects were calculated using logistic regression. Variables
included in the propensity score calculation were considered
to be satisfactorily matched if the absolute standardized
difference in value between the 2 groups was <0.1.
Comparisons of healthcare resource use and costs between
study patients and controls were performed using Yate’s chi-
squared test, Fisher’s exact test, and Wilcoxon’s signed-rank
test. To reduce the influence of unobserved factors and
selection bias on cost comparisons, difference-in-differences
methodology, based on a comparison of the average change
in costs over time between study patients and controls, was
used to determine the differential effect of nAMD. Statistical
analyses were performed using SAS version 9.4 (SAS Institute
Inc. Cary, NC, USA).
Results
Study participants
Of a total of 528,625 adults continuously enrolled in the EGB
database from 2009 to 2017, 2,239 patients aged 50 years
had 2 reimbursement claims for ranibizumab, aflibercept,
bevacizumab, or intravitreal injection during 2014–2017.
After excluding patients with other possible indications for
intravitreal anti-VEGF therapy, 1,126 patients were confirmed
as receiving treatment specifically for nAMD over this period.
Within this cohort, 355 patients were identified as initiating
anti-VEGF treatment for newly diagnosed nAMD during
2014–2015 (‘study population’) (Figure 1), of whom 345 and
333 patients provided follow-up data at 12 and 24 months,
respectively. Among the study population, 42 patients
(11.8%) received their first and second intravitreal injections
less than 3 weeks apart, suggesting possible bilateral disease
in these cases.
The control group comprised 1,065 anti-VEGF treatment-
naïve subjects with no recorded nAMD diagnosis, aged 50
years, who were propensity score-matched (3:1) to the inci-
dent nAMD population.
Baseline demographic and clinical characteristics of the
incident nAMD and control populations
The study population (n¼ 355) had a mean age of 79.5
(range, 50–97) years at index date (baseline) and was pre-
dominantly female (65.9%) and geographically diverse, with
the highest representation in the Ile-de-France, Auvergne-
Rhône-Alpes, Grand Est, Hauts-de France, Normandie, and
Nouvelle Aquitaine regions. The mean (SD) CCI score at base-
line was 4.5 (2.0), with the majority of patients (87%) having
a CCI score 3 (Table 1). Nearly one-half of patients (48.5%)
presented with one or more long-term diseases during the
5-year pre-index period, including lymphatic or hematopoi-
etic malignancies (13.5%), severe heart diseases such as heart
1090 J.-F. KOROBELNIK ET AL.
failure, cardiac arrhythmia, valvular and congenital heart dis-
ease (9%), and coronary artery disease (8.2%). The most fre-
quent medical events of interest over this period were
cardiovascular disease (75.2%), anxiety/depression (38.6%),
fractures (6.8%), and falls (3.1%). One-third of patients
(33.8%) had 1 ocular comorbidity, including cataract
(22.8%) and glaucoma (14.4%). Almost all patients (95.8%)
had received an ocular procedure/examination (OCT, fluores-
cein/indocyanine green angiography, and/or fundoscopy)
during the 6-month pre-index period; a small minority (6.2%)
had undergone ocular (predominantly cataract) surgery
(Table 1).
The control group (N¼ 1,065) closely matched the study
population with respect to the propensity score variables,
namely age (mean 79.8 vs. 79.5 years), gender (34.0% vs.
34.1% male), geographic distribution, CCI score (mean 4.4 vs.
4.5), and presence of cardiovascular disease (75.8% vs.
75.2%) and respiratory disease (7.0% vs. 6.8%) (Table 1). The
sole anomaly was a lower frequency of prior cataract surgery
in the control group compared to the patient group (2.8%
vs. 5.9%); however, the absolute standardized difference
after propensity score matching was low (–0.17), suggesting
that this variable was adequately balanced between the
2 groups.
Anti-VEGF treatment patterns in the incident nAMD
population
Among the study population (n¼ 355), the most frequently
administered anti-VEGF agent during follow-up (24 months)
was ranibizumab (73.2% of patients), followed by aflibercept
(43.1%) and bevacizumab (0.6%). Patients received their anti-
VEGF injections predominantly in the outpatient setting
(96.9%), and only occasionally as inpatients (8.7%). On aver-
age, each patient received 5.2 (SD 2.9) intravitreal anti-VEGF
injections over months 0–12 (n¼ 345), and 2.4 (SD 3.3) injec-
tions over months 12–24 (n¼ 333).
For those patients with information on treatment continu-
ity (n¼ 343), 79.0% (n¼ 271) remained on their initial (index)
anti-VEGF agent during follow-up, whereas 11.7% (n¼ 40)
experienced one switch of an anti-VEGF agent, 7.0% (n¼ 24)
had an unknown number of treatment switches, and 2.3%
(n¼ 8) had treatment switch-back. For patients with a single
treatment switch (n¼ 40), the most frequent transitions were
ranibizumab to aflibercept (n¼ 31, 75.5%) and aflibercept to
ranibizumab (n¼ 8, 20%). The mean (SD) time to first switch
after initiating anti-VEGF treatment was 8.8 (SD 6.0) months,
and 72.5% of switches (n¼ 29) occurred within the first
12 months.
Table 1. Baseline demographic and clinical characteristics of the incident nAMD and control populations.
Characteristic Incident nAMD Control group
(N¼ 355) (N¼ 1,065)
Age, years, mean (SD) 79.5 (9.5) 79.8 (9.7)
Age group, n (%)
<70 years 61 (17.2) N/A
70–80 years 83 (23.4) N/A
80–90 years 167 (47.0) N/A
>90 years 44 (12.4) N/A
Gender female, n (%) 234 (65.9) 703 (66.0)
Geographic area, n (%)
Île-de-France 51 (14.4) 141 (13.3)
Auvergne-Rhône-Alpes 44 (12.4) 125 (11.8)
Grand Est 37 (10.5) 101 (9.5)
Hauts-de-France 31 (8.8) 101 (9.5)
Normandie 30 (8.5) 97 (9.1)
Nouvelle-Aquitaine 29 (8.2) 98 (9.2)
Provence-Alpes-Côte d’Azur 27 (7.6) 80 (7.5)
Bretagne 25 (7.1) 92 (8.7)
Occitanie 24 (6.8) 66 (6.2)
Centre-Val de Loire 20 (5.6) 59 (5.6)
Pays de la Loire 19 (5.4) 50 (4.7)
Bourgogne-Franche-Comte 13 (3.7) 45 (4.2)
Other/unknown 5 (1.4) 10 (0.9)
Charlson Comorbidity Index, mean (SD)a 4.5 (2.0) 4.4 (1.8)
Medical conditions of interest in past 5 years, n (%)
Cardiovascular disease 267 (75.2) 807 (75.8)
Anxiety/depression 137 (38.6) N/A
Cataract 81 (22.8) N/A
Glaucoma 51 (14.4) N/A
Falls/fractures 35 (9.9) N/A
Respiratory disease 24 (6.8) 75 (7.0)
Ocular procedures/surgeries in past 6 months, n (%)
Ocular coherence tomography 322 (90.7) 53 (5.0)
Fluorescein/indocyanine green angiography 157 (44.2) 0 (0)
Fundoscopy 150 (42.3) 61 (5.7)
Cataract surgery 21 (5.9) 30 (2.8)
Glaucoma surgery 2 (0.6) 1 (0.1)
aCharlson Comorbidity Index, a weighted, age-adjusted estimate of mortality risk based on the presence and severity of 19
comorbid conditions, with higher Charlson Comorbidity Index scores correlated with reduced 10-year survival.
Abbreviations. nAMD, Neovascular age-related macular degeneration; N/A, Not available; SD, Standard deviation.
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Most study patients (82.3%) were prescribed an adjunctive
eyedrop for use with each intravitreal anti-VEGF injection;
the most frequently prescribed medication types were top-
ical antibiotics (71.0% of the study population), antiseptics
(28.7%) and corticosteroid–antibiotic combinations (19.7%).
In accordance with changes to guideline recommendations,
the proportion of intravitreal anti-VEGF injections preceded
by an antibiotic eyedrop prescription declined over the study
period, from 67.1% in 2014 to 29.2% in 2017.
Healthcare resource utilization in the incident nAMD
population
Outpatient visits, emergency department visits, and
hospitalizations
Nearly all patients in the study population (n¼ 355) had one
or more outpatient visits of interest (99.7%) during follow-up,
including ophthalmology visits (99.7%) and general practice
visits (87.3%), and 36.3% of patients had one or more emer-
gency department visits (Table 2). Overall, 13.8% of patients
had one or more hospitalizations of interest; this included
hospitalizations due to falls/fractures (9.3%), thromboembolic
events (2.3%), myocardial infarction (2.0%), and nAMD (1.7%)
(Table 2). Over the entire 24 months post-index (n¼ 333),
patients had on average 25.8 (SD 16.5) ophthalmology visits,
9.1 (SD 7.3) general practice visits, 0.6 (SD 1.0) emergency
department visits, and 0.2 (SD 0.5) hospitalizations of inter-
est. For hospitalized patients, the average total duration of
hospital stay was 11.5 (SD 10.5) days per annum.
Ocular examinations/procedures
Almost all patients in the study population (n¼ 355) were
documented as undergoing 1 ocular examination/proced-
ure of interest (96.9%) during follow-up, including OCT
(95.8%), fundoscopy (47.9%), and angiography (28.5%). On
average, over 24 months post-index, users underwent 14.7
(SD 9.9) OCT, 5.4 (SD 6.0) fundoscopy, and 2.2 (SD 1.6) angi-
ography procedures. A minority of patients underwent ocular
surgery during follow-up (13.5%), including cataract surgery
(13.0%), glaucoma surgery (0.6%), and surgery for retinal
detachment (0.8%).
Table 2. Healthcare resource utilization during follow-up (24 months) in the incident nAMD and control populations.
Incident nAMD patients Control subjects p-value
(N¼ 355) (N¼ 1,065)
Outpatient visits of interest
Patients with 1 visit, n (%)
Any outpatient visit of interest 354 (99.7) 943 (88.5) <.001
Ophthalmology 354 (99.7) 477 (44.8) <.001
General practice 310 (87.3) 901 (84.6) .243
No. unique visits per patient, mean (SD)
Ophthalmology 25.1 (16.4) 1.2 (1.9) <.001
General practice 8.9 (7.3) 8.6 (8.0) .222
Emergency department visits
Patients with 1 visit, n (%) 129 (36.3) 363 (34.1) .479
No. unique visits per patient, mean (SD) 0.7 (1.2) 0.6 (1.1) .319
Hospitalizations of interest
Patients with 1 hospitalization, n (%)
Any hospitalization of interest 49 (13.8) 122 (11.5) .279
Myocardial infarction 7 (2.0) 10 (0.9) .155
Thromboembolic event 8 (2.3) 26 (2.4) 1.000
Fall/fracture 33 (9.3) 97 (9.1) 1.000
nAMD 6 (1.7) 0 (0) <.001
No. hospitalizations per patient, mean (SD)
Hospitalizations of interest 0.2 (0.5) 0.1 (0.5) .224
Days of hospital stay per year, mean (SD)a 1.6 (5.5) 1.5 (5.4) .292
Sick leaves
Patients with 1 sick leave, n (%) 4 (1.1) 10 (0.9) .759
Days of sick leave per year, mean (SD)b 1.2 (12.7) 1.6 (26.8) .753
Medical transports
Patients with 1 transport event, n (%) 135 (38.0) 340 (31.9) .041
No. unique events per patient, mean (SD)a 6.0 (32.7) 3.5 (27.6) .006
Ocular procedures of interest
Patients with 1 event, n (%)
Ocular coherence tomography 340 (95.8) 161 (15.1) <.001
Fundoscopy 170 (47.9) 184 (17.3) <.001
Angiography 101 (28.5) 9 (0.8) <.001
Ocular surgery of interest
Patients with 1 event, n (%)
Cataract surgery 46 (13.0) 71 (6.7) <.001
Retinal detachment 3 (0.8) 0 (0) .016
Glaucoma surgery 2 (0.6) 4 (0.4) .644
Event rates are expressed for the overall population (n¼ 355 study patients; n¼ 1,065 control subjects) and are derived over a
variable (24 months) follow-up period.
aMean cumulative length of hospital stay among patients undergoing hospitalization (n¼ 49 for study patients; n¼ 122 for con-
trol subjects).
bMean cumulative length of sick leave among the overall population (n¼ 355 study patients; n¼ 1,065 control subjects).
Abbreviations. nAMD, Neovascular age-related macular degeneration; SD, Standard deviation.
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Sick leave and medical transports
Over the follow-up period, 38.0% of patients in the incident
nAMD cohort had one or more reimbursed medical trans-
ports, and 1.1% of patients in this predominantly retirement-
age population had one or more reported sick leaves.
Comparison of healthcare resource use and costs in the
incident nAMD and control populations
Healthcare resource use
Healthcare resource utilization during follow-up was gener-
ally lower among control subjects than among patients with
incident anti-VEGF–treated nAMD (Table 2). This was
reflected in significantly smaller percentages of control sub-
jects experiencing an outpatient ophthalmology visit (44.8%
vs. 99.7%; p<.001), an ocular procedure (i.e. OCT, angiog-
raphy, or fundoscopy) (27.2% vs. 96.9%; p<.001), cataract sur-
gery (6.7% vs. 13.0%; p<.001), and medical transport (31.9%
vs. 38.0%; p¼.041), and, at the individual level, significantly
fewer outpatient ophthalmology visits (mean 1.2 vs. 25.1;
p<.001) and medical transports (mean 3.5 vs. 6.0; p¼.006). In
contrast, the proportions of patients with general practice
and emergency department visits, non-AMD-related hospital-
izations (i.e. admissions for myocardial infarction, thrombo-
embolic events, or falls/fractures), and sick-leave absences
were similar in the 2 populations, as were the average num-
bers of GP visits, emergency department visits, hospitaliza-
tions of interest, and sick days per patient (Table 2).
Healthcare costs
Total reimbursed costs per patient during follow-up were
two-fold higher for the incident nAMD population (mean
e16,799) than for the control group (mean e8,255) (Table 3).
Compared with control subjects, patients with incident
nAMD had higher treatment costs (mean e6,847 vs. e1,156
per patient) and medical fees (mean e1,858 vs. e295 per
patient), but similar hospital fees (mean e6,396 vs. e5,235
per patient), paramedical fees (mean e1,309 vs. e1,321 per
patient), transport costs (mean e358 vs. e259 per patient)
and optical equipment costs (mean e5 vs. e4 per patient).
For the incident nAMD population, treatment costs repre-
sented the largest percentage of all reimbursed costs (41%),
followed by hospital fees (38%), medical fees (11%), para-
medical fees (8%), and transport costs (2%) (Figure 2). Cost
comparisons, which were adjusted to capture the additional
cost of nAMD diagnosis in the study population, indicated
significant increases in total costs of (mean) e5,279 per
patient (p<.05) for study patients relative to controls over
the period from 6 months pre-index to 12 months post-index
and e7,918 per patient (p<.0001) over the period 6 months
pre-index to 24 months post-index. These increases in total
costs were attributable to significant (p<.0001) differential
increases in treatment costs (mean e4,096 and e5,751 per
patient) and medical fees (mean e1,061 and e1,612 per
patient) over the 6 to 12-month and 6 to 24-month time-
frames, respectively. In contrast, no significant divergence in
hospital fees, paramedical fees, or transport costs was
observed between study patients and controls over either
period.
Epidemiological projections
Over the period 2014–2017, the number of incident cases of
anti-VEGF–treated nAMD identified in the EGB database
showed a slight year-on-year increase, rising from 200 (0.11%
of the database population) in 2014 to 220 (0.12%) in 2015,
229 (0.13%) in 2016, and 247 (0.14%) in 2017. Projection of
the most recent (2017) annual incidence figure to the
national population resulted in an estimate of 34,134 (95%
CI, 33,774 to 34,498) newly treated nAMD patients in France
in 2017.
Table 3. Reimbursed healthcare resource costs (2018 Euro values) per patient during follow-up (24 months) for the incident
nAMD and control populations.
Incident nAMD patients Control subjects
(N¼ 355) (N¼ 1,065)
Hospitalizations and surgery
Mean (SD) 6,396 (14,409) 5,235 (13,250)
Median (IQR) 490 (0–6,407) 22 (0–3,640)
Treatment
Mean (SD) 6,847 (4,717) 1,156 (3,699)
Median (IQR) 5,602 (3,555–8,717) 561 (237–1,154)
Medical fees (outpatient visits)
Mean (SD) 1,858 (1,686) 295 (296)
Median (IQR) 1,441 (810–2,298) 238 (108–390)
Paramedical fees (nurse, physiotherapist, orthoptist)
Mean (SD) 1,309 (4,413) 1,321 (4,454)
Median (IQR) 117 (13–595) 57 (4–547)
Medical transports
Mean (SD) 358 (1,994) 259 (2,575)
Median (IQR) 0 (0–202) 0 (0–104)
Optics
Mean (SD) 5 (8) 4 (8)
Median (IQR) 0 (0–11) 0 (0–5)
Total cost
Mean (SD) 16,799 (17,636) 8,255 (16,567)
Median (IQR) 11,565 (6,614–20,635) 2,010 (669–8,166)
Abbreviations. IQR, Interquartile range; nAMD, Neovascular age-related macular degeneration; SD, Standard deviation.
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Discussion
The principal objective of this analysis of the EGB database
was to provide a picture of anti-VEGF treatment patterns,
healthcare resource demands, and associated costs specific
to nAMD in the real-world setting. Consistent with the previ-
ous reports15,18,33, our analysis of reimbursement claims indi-
cates that ranibizumab was the most widely used anti-VEGF
agent for the treatment of incident nAMD in French clinical
practice during 2014–2017, followed by aflibercept, with bev-
acizumab used only rarely, and that the vast majority of
intravitreal anti-VEGF injections (97%) were performed in the
outpatient setting. It is also apparent from our analysis that
despite regular patient follow-up (as reflected in a mean of
15.6 and 10.2 outpatient ophthalmology visits in Years 1 and
2, respectively) and regular monitoring of disease activity
(mean 8.1 and 6.0 OCT examinations during Years 1 and 2,
respectively), study patients were treated considerably less
frequently (mean 5.2 and 2.4 anti-VEGF injections per patient
during Years 1 and 2, respectively) than patients participat-
ing in randomized clinical trials of monthly, pro re nata
(PRN), and treat-and-extend regimens such as ANCHOR,
HARBOR, VIEW, TREX-AMD, CATT, and TREND34–39. Moreover,
given that some 12% of the study population were possibly
receiving bilateral anti-VEGF treatment, the mean injection
frequency at eye level is likely to have been even lower. This
finding is mirrored by previous real-world studies of anti-
VEGF (predominantly ranibizumab) use in nAMD, which have
indicated generally low injection frequencies (4 to 6 per
patient in the first year, and 3 to 4 in the second
year)14,15,40–46. Set against the backdrop of close ophthalmo-
logical monitoring, the low frequency of anti-VEGF injections
in French clinical practice is indicative of increasing use by
ophthalmologists of discontinuous (PRN and/or treat-and-
extend) dosing strategies in the management of nAMD
rather than to failings in patient follow-up.
An additional factor likely to influence anti-VEGF treat-
ment frequency in routine clinical practice is the level of
treatment reimbursement. As a country with a full reimburse-
ment healthcare system, France may be expected to have
higher intravitreal anti-VEGF injection frequencies and hence
higher anti-VEGF treatment costs per patient than those
countries operating under partial reimbursement or self-paid
systems. The observational UNCOVER (Unraveling nAMD real-
life Clinical management and Outcome with intravitreal
Ranibizumab injection) study, which assessed intravitreal
ranibizumab treatment patterns and vision outcomes in
nAMD patients across various reimbursement scenarios in
the Middle East, North Africa and the Asia Pacific region,
reported average annual intravitreal injection frequencies
(over a 1- to 3-year period) of 2.6 in self-paid, 4.1 in partially
reimbursed and 4.7 in full reimbursed populations47.
However, the average annual number of anti-VEGF injections
received by patients in France remains low, particularly after
the first year of treatment, suggesting that any reimburse-
ment advantage is offset by other factors.
In keeping with previous reports that switching between
anti-VEGF agents is uncommon in the treatment of nAMD48,
the analysis indicated that most (79.0%) study patients
remained on their initial anti-VEGF agent for the duration of
follow-up. When treatment switching did occur, it was imple-
mented on average 9 months after starting treatment, and
typically involved the replacement of ranibizumab (the most
commonly used index treatment) with aflibercept.
Overall healthcare resource utilization over the 24-month
follow-up period was higher for nAMD patients initiating
anti-VEGF therapy than for propensity score-matched con-
trols, as reflected in the greater proportions of study patients
with outpatient ophthalmology visits, ocular procedures,
cataract surgery, retinal detachment surgery, and medical
transports. Most of this excess healthcare resource use
occurred in the first year of treatment. The increased require-
ment for cataract and retinal detachment surgery among
nAMD patients may be ascribed respectively to preferential
ophthalmological screening resulting in more diagnoses of
lens opacification, and the risk, albeit slight, of rhegmatoge-
nous retinal detachment with intravitreal anti-VEGF ther-
apy49. Of note, however, no differences were found between
patients and their controls with respect to numbers of emer-
gency department visits, non–AMD-related hospitalizations,
and sick leaves.
Total reimbursed costs for incident nAMD patients
exceeded those of control subjects by e5,279 per patient
over the period from 6 months before to 12 months after ini-
tiation of anti-VEGF treatment and by e7,918 per patient
over the period from 6 months before to 24 months after
treatment initiation, with the largest contributors to this cost
differential being treatment costs (mean excess e5,751 per
patient over 2 years) and medical fees (mean excess e1,612
per patient over 2 years). Thus, the economic burden of
nAMD management is mainly due to intravitreal anti-VEGF
injection costs and patient monitoring costs, notably those
arising from frequent ophthalmology visits and OCT proce-
dures. In contrast, costs associated with the use of other














Figure 2. Distribution of reimbursed healthcare costs of study patients over 24
months of follow-up.
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healthcare resources, such as hospital and paramedical serv-
ices and medical transports, have marginal impact on the
overall economic burden of nAMD.
Our analysis of the EGB database also provided the
opportunity to estimate the current incidence of anti-VEGF-
treated nAMD in France. Comprehensive national epidemio-
logical figures for nAMD are required to assist proper
planning for public health and ophthalmology policy makers.
Since the EGB database does not specify the reason for
administering anti-VEGF treatment, our approach was to
identify all anti-VEGF–treated patients and then exclude
those patients who may have received treatment for non-
AMD–related indications (i.e. retinal vein occlusion, diabetic
macular edema, diabetic retinopathy, and myopic choroidal
neovascularization), as well as patients with nAMD coexisting
with other retinal diseases. Numerical projections from the
EGB database population, adjusted for gender and age differ-
ences, indicated that there were an estimated 34,134 inci-
dent cases of anti-VEGF–nAMD in France in 2017,
representing 0.13% of the French population aged 50 years
(estimated at 26.6 million in January 2020)9. Taking into
account the different age profile of the various epidemio-
logical survey populations, this estimate is broadly consistent
with findings from the few published studies describing the
incidence of nAMD in large, population-based cohorts in
France. Thus, in the POLA (Pathologies Oculaires Liees a
l’Age) study, a population-based prospective cohort study
conducted in 1995–2000, the 3-year incidence of nAMD was
reported to be 0.49% (95% CI, 0.13%–0.85%) among subjects
60 years of age50. As part of the European Eye
Epidemiology (E3) Consortium, 2 French prospective cohort
studies, ALIENOR-3C (Antioxydants, Lipids Essentials,
Nutrition et Maladies Oculaires), conducted in 2006–2012 in
subjects 70 years, and Montrachet-3C (conducted in
2009–2013 in subjects 75 years) reported crude prevalence
rates for late nAMD of 5.6% and 2.2%, respectively7.
Likewise, as part of the European Eye Study (EUREYE), a
multinational cohort study to assess the prevalence of age-
related maculopathy in the elderly, the participating French
study centre (Paris-Creteil) reported a prevalence rate for
nAMD of 3.0% among subjects 65 years of age8. Long-term
follow-up findings from a small cohort of elderly (73 years)
Bordeaux residents (n¼ 659) participating in the ALIENOR-3C
study (2006–2012) indicated that the 5-year risk of incident
nAMD in this population was 4.4%51. Overall, these findings
would tend to suggest overall stability in the incidence and
prevalence of nAMD in France over the past 20 years.
There are several limitations associated with the analysis
of reimbursement claims, including potential shortcomings in
the accuracy and completeness of the database record.
Administrative claims databases are designed to manage
healthcare transactions and generally do not provide com-
prehensive information on diagnoses, linked prescriptions,
and clinical outcomes. In addition, ophthalmological datasets
generally do not specify the laterality of treatment, which
adds uncertainty to the interpretation of injection frequency
and treatment switch data. (This is pertinent to our analysis
since 12% of study patients were potentially receiving
bilateral treatment.) A specific limitation of the EGB database
is that it is underpowered to identify clinical events with low
incidence rates. Moreover, in keeping with its specific pur-
pose—to estimate the economic burden associated with
management of incident nAMD with anti-VEGF therapy in
clinical practice—the study excluded treatment-naïve
patients and patients with concomitant ocular disease and is
therefore likely to have underestimated the actual incidence
of nAMD diagnosis in the French population. Finally,
although attempts were made to ensure comparability of the
study and control groups through propensity score-matching
based on socio-demographic (age, gender, region of resi-
dence) and clinical variables (cardiovascular disease, respira-
tory disease, previous cataract surgery and Charlson
comorbidity index), the quality of the matching may have
been limited by a shortage of clinical data in the EGB
database.
In conclusion, the high acquisition costs of current intravi-
treal anti-VEGF therapy, coupled with the requirement for
regular (monthly or near-monthly) follow-up and monitoring
of patients initiating such treatment for nAMD, place a con-
siderable economic burden on the French healthcare system.
Future intravitreal therapies that offer extended dosing inter-
vals and predictable efficacy would have the potential
advantage of reducing overall demand for medical services.
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